Diffuse Systemic Sclerosis Clinical Trial
Official title:
OPEN LABEL TRIAL OF ANTI-TGF-BETA MAB, FRESOLIMUMAB, IN SYSTEMIC SCLEROSIS - A PHASE ONE BIOMARKER TRIAL
The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01586663 -
Serial Night Time Position Splint on Systemic Sclerosis
|
Phase 3 | |
Completed |
NCT01538719 -
IL1-TRAP, Rilonacept, in Systemic Sclerosis
|
Phase 1/Phase 2 | |
Terminated |
NCT04837131 -
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
|
Phase 2 |